Tumor cells with impaired antiviral defense pathways

Tumor cells with impaired antiviral defense pathways represent a cellular phenotype characterized by defects in innate immunity, most notably the type I interferon (IFN) signaling cascade. During oncogenesis, cancer cells frequently lose the ability to produce or respond to interferons—through mutations in genes like JAK1, STAT1, or IRF3—to avoid growth arrest and immune detection (Source: Xia et al., 2016, Cell Reports). This vulnerability is exploited by oncolytic viruses, which are engineered or naturally predisposed to replicate selectively in cells that cannot mount an effective antiviral response (Source: Kaufman et al., 2015, Nature Reviews Drug Discovery). While healthy cells use intact IFN pathways to suppress viral replication, the impaired defenses in tumor cells allow the virus to proliferate, leading to direct oncolysis. This process subsequently releases tumor-associated antigens and pro-inflammatory cytokines, transforming the tumor microenvironment and promoting a systemic T-cell mediated anti-tumor response (Source: Bommareddy et al., 2018, Nature Reviews Immunology). Consequently, this impaired defense state serves as a functional target for various viral-based immunotherapies currently in clinical development. These therapies aim to turn "cold" tumors "hot" by leveraging the inherent signaling deficiencies of the malignant cells. The selectivity of these agents depends heavily on the differential antiviral capacity between cancerous and normal tissues.

Other names

Interferon-deficient tumor cellsAntiviral-deficient cancer cellsOncolytic virus-susceptible tumor cellsIFN-pathway defective cancer cells

Selective viral replication within cells lacking functional innate antiviral signaling (primarily the type I interferon pathway), leading to direct cellular lysis and the subsequent induction of a systemic anti-tumor immune response.